<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?>
<document xmlns:voc="http://www.hl7.org/v3/voc" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="6DC2E2DE-4061-41DD-A35D-7D12507C517F" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">Priscoline hydrochloride injection<sup>&#174;</sup></title>
<effectiveTime value="20060601" />
<setId root="6DC2E2DE-4061-41DD-A35D-7D12507C517F" />
<versionNumber value="1" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Novartis Pharmaceuticals Corporation</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="BE5D28D0-35ED-3E1F-668D-667B5B07144F" />
<effectiveTime value="20060601" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0083-6733" codeSystem="2.16.840.1.113883.6.69" />
<name>Priscoline hydrochloride</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="25">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="25" />
</numerator>
<denominator unit="mL" value="1">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="E669Z6S1JG" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>tolazoline hydrochloride</name>
<activeMoiety>
<activeMoiety>
<name>tolazoline</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>tolazoline hydrochloride</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<quantity>
<numerator unit="mg" value="6.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="6.5" />
</numerator>
<denominator unit="mL" value="1">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<name>hydrous sodium citrate</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<quantity>
<numerator unit="mg" value="6.5">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="6.5" />
</numerator>
<denominator unit="mL" value="1">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="1" />
</denominator>
</quantity>
<inactiveIngredientSubstance>
<code code="W4888I119H" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>tartaric acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="4">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="4" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code />
<formCode code="C43165" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AMPULE" />
<asContent>
<quantity>
<numerator value="4">
<translation code="C48473" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="AMPULE" value="4" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0083-6733-04" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON" />
</containerPackagedMedicine>
</asContent>
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="60448676-D6BB-6DBC-84E5-BE70A53BEADB" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml" />
<text><paragraph>C98-24<br />665480</paragraph><paragraph><content styleCode="bold">&#160;&#160;&#160;&#160;&#160;
	Priscoline&#174; hydrochloride</content></paragraph><paragraph><content styleCode="bold">&#160;&#160;&#160;&#160;&#160;
	tolazoline hydrochloride injection, USP</content></paragraph><paragraph><content styleCode="bold">&#160;&#160;&#160;&#160;&#160;
	Ampuls</content></paragraph><paragraph><content styleCode="bold">&#160;&#160;&#160;&#160;&#160;
	Rx only</content></paragraph><paragraph><content styleCode="bold">&#160;&#160;&#160;&#160;&#160;
	Prescribing Information</content></paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="4C7DCA06-112D-C2AD-5C81-1EF6D39C8BA7" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DESCRIPTION</content></title>
<text><paragraph>Priscoline hydrochloride, tolazoline hydrochloride injection, USP, is a peripheral vasodilator available in ampuls for intravenous administration. Each milliliter of sterile, aqueous solution contains tolazoline hydrochloride USP, 25 mg; tartaric acid ACS, 6.5 mg; and hydrous sodium citrate USP, 6.5 mg. Tolazoline hydrochloride is 4,5-dihydro-2-(phenylmethyl)-<br />1<content styleCode="italics">H</content>-imidazole monohydrochloride, and its structural formula is</paragraph><paragraph><renderMultiMedia referencedObject="MM03000002" /></paragraph><paragraph>Tolazoline hydrochloride USP is a white to off-white crystalline powder. Its solutions are slightly acid to litmus. It is freely soluble in water and in alcohol. Its molecular weight is 196.68.</paragraph></text>
<effectiveTime value="20060601" />
<component>
<observationMedia ID="MM03000002">
<value mediaType="image/jpeg" xsi:type="ED"><reference value="priscolinehydrochlorideinjection-figure-02.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="DF7BC180-6142-23C2-B858-83792D6797AD" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">CLINICAL PHARMACOLOGY</content></title>
<text><paragraph>Priscoline is a direct peripheral vasodilator with moderate competitive alpha-adrenergic blocking activity. It decreases peripheral resistance and increases venous capacitance. It has the following additional actions:  (1) sympathomimetic, including cardiac stimulation; (2) parasympathomimetic, including gastrointestinal tract stimulation that is blocked by atropine; and (3) histamine-like, including stimulation of gastric secretion and peripheral vasodilatation. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance.</paragraph><paragraph>In neonates the half-life of Priscoline ranges from 3 to 10 hours.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="A1DB9FAB-A985-60E3-6357-F9C5126DF23F" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS AND USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">INDICATIONS AND USAGE</content></title>
<text><paragraph>Priscoline is indicated for the treatment of persistent pulmonary hypertension of the newborn (&#8220;persistent fetal circulation&#8221;) when systemic arterial oxygenation cannot be satisfactorily maintained by usual supportive care (supplemental oxygen and/or mechanical ventilation).</paragraph><paragraph>Priscoline should be used in a highly supervised setting, where vital signs, oxygenation, acid-base status, fluid, and electrolytes can be monitored and maintained.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="76A4CEAF-E39A-C2E2-2F57-3C3770A36FE7" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">CONTRAINDICATIONS</content></title>
<text><paragraph>Priscoline is contraindicated in patients with hypersensitivity to tolazoline.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="0637EB03-FCEB-EBD6-4FF0-04BD53FBCD03" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">WARNINGS</content></title>
<text><paragraph>Priscoline stimulates gastric secretion and may activate stress ulcers. Through this mechanism, it can produce significant hypochloremic alkalosis.  Pretreatment of infants with antacids may prevent gastrointestinal bleeding.</paragraph><paragraph>Patients should be observed closely for signs of systemic hypotension, and supportive therapy should be instituted if needed.</paragraph><paragraph>In patients with mitral stenosis, parenterally administered  Priscoline may produce a rise or fall in pulmonary artery pressure and total pulmonary resistance; therefore, it  must  be  used with caution in patients with known or suspected mitral stenosis.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="BF59C099-7087-A1F4-AAAB-842A952B49D3" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">PRECAUTIONS</content></title>
<text />
<effectiveTime value="20060601" />
<component>
<section>
<id root="2D6470A4-E89D-C082-EBC0-71DAC0DBDC89" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">General</content></title>
<text><paragraph>The effects of Priscoline on pulmonary vessels may be pH dependent. Acidosis may decrease the effect of Priscoline.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="35266AD3-759E-BB6D-D54B-B0A55544F818" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content></title>
<text><paragraph>Long-term carcinogenicity studies in animals have not been performed with Priscoline.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="F4E731AF-8A5A-7F5D-DD19-EF38C404D236" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Pregnancy Category C</content></title>
<text><paragraph>Animal reproduction studies have not been conducted with Priscoline. It is also not known whether Priscoline can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Priscoline should be given to a pregnant woman only if clearly needed.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="2C923A48-DDEE-D03D-F5A4-2913E7D5453D" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Nursing Mothers</content></title>
<text><paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Priscoline is  administered  to a nursing woman.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="36B304B1-24C5-C7AE-EB9B-B9F77910182C" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Pediatric Use</content></title>
<text><paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="2BEBA3D1-1688-D64E-E20B-1F3CDC532835" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">ADVERSE REACTIONS</content></title>
<text><paragraph>The following adverse reactions have been observed, but there are insufficient data to support an estimate of their frequency:</paragraph><paragraph><content styleCode="bold italics">Cardiovascular</content>:  Hypotension, tachycardia, cardiac arrhythmias, hypertension, pulmonary hemorrhage.</paragraph><paragraph><content styleCode="bold italics">Digestive and Hepatic</content>:  Gastrointestinal hemorrhage, nausea, vomiting, diarrhea, hepatitis.</paragraph><paragraph><content styleCode="bold italics">Skin</content>:  Flushing, increased pilomotor activity with tingling or chilliness, rash.</paragraph><paragraph><content styleCode="bold italics">Hematologic</content>:  Thrombocytopenia, leukopenia.</paragraph><paragraph><content styleCode="bold italics">Renal</content>:  Edema, oliguria, hematuria.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="3B2EDC7E-AF10-003C-5385-AAB06C9CF303" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">OVERDOSAGE</content></title>
<text />
<effectiveTime value="20060601" />
<component>
<section>
<id root="30EC8810-0780-E464-5D1E-17E43ED061B8" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Acute Toxicity</content></title>
<text><paragraph>Oral LD<sub>50</sub>&#8217;s (mg/kg): mice, 400; rats, 1200.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="9573129A-D380-7FAC-531B-1984F831B793" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Signs and Symptoms</content></title>
<text><paragraph>Signs and symptoms of overdosage may include increased pilomotor activity, peripheral vasodilatation, skin flushing, and, in rare instances, hypotension and shock.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="064A32C1-2AD2-62B5-EA65-9E9E1FE88626" />
<code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">Treatment</content></title>
<text><paragraph>In treating hypotension, it is most important to place the patient&#8217;s head low and administer intravenous fluids. Epinephrine should not be used, since large doses of Priscoline may cause &#8220;epinephrine reversal&#8221; (further reduction in blood pressure, followed by an exaggerated rebound).</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="B31F1837-8938-82C1-BE32-6EB47E6A4891" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DOSAGE AND ADMINISTRATION</content></title>
<text><paragraph>An initial dose of 1 to 2 mg/kg, via scalp vein, followed by an infusion of 1 to 2 mg/kg per hour have usually resulted in significant increases in arterial oxygen. There is very little experience with infusions lasting beyond 36 to 48 hours. Response, if it occurs, can be expected within 30 minutes after the initial dose.</paragraph><paragraph><content styleCode="bold italics">Note</content>:  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
<component>
<section>
<id root="23BF562B-4C6B-8B21-1FF3-7C7B87EB422C" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">HOW SUPPLIED</content></title>
<text><paragraph><content styleCode="italics">Ampuls</content>  4 mL&#8212; each milliliter contains 25 mg of tolazoline hydrochloride.</paragraph><paragraph>Carton of 4 ampuls&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.NDC 0083-6733-04</paragraph><paragraph /><paragraph>Store between 15&#186;C and 30&#186;C (59&#186;F-86&#186;F). </paragraph><paragraph><content styleCode="italics">Protect from light.</content></paragraph><paragraph /><paragraph>665480                                         &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
	C98-24 (Rev. 9/98)</paragraph><paragraph /><paragraph /><paragraph /><paragraph /><paragraph /><paragraph>Distributed by</paragraph><paragraph>Novartis Pharmaceuticals Corporation</paragraph><paragraph>East Hanover, New Jersey  07936</paragraph><paragraph /><paragraph>&#169;1998 Novartis</paragraph></text>
<effectiveTime value="20060601" />
</section>
</component>
</structuredBody>
</component>
</document>
